NET | Monoamine transporter subfamily | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲


Target not currently curated in GtoImmuPdb

Target id: 926

Nomenclature: NET

Systematic Nomenclature: SLC6A2

Family: Monoamine transporter subfamily

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 12 617 16q12.2 SLC6A2 solute carrier family 6 member 2
Mouse 12 617 8 44.99 cM Slc6a2 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2
Rat - - 19p11 Slc6a2 solute carrier family 6 member 2
Previous and Unofficial Names
NAT1 | NET1 | SLC6A5 | NaCl-dependent norepinephrine transporter | norepinephrine transporter | sodium-dependent noradrenaline transporter | NE transporter | solute carrier family 6 (neurotransmitter transporter), member 2 | solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | solute carrier family 6 (neurotransmitter transporter
Database Links
Specialist databases
Bioparadigms SLC Tables SLC6A2 (Hs)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
Substrates and Reaction Kinetics
Substrate Sp. Property Value Units Standard property Standard value Assay description Assay conditions Comments Reference
(-)-adrenaline Hs -
(-)-noradrenaline Hs -
dopamine Hs -
MPP+ Hs -
methamphetamine Hs -
amphetamine Hs -
1 noradrenaline: 1 Na+:1 Cl- [8]

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[3H]mazindol Rn Inhibition 9.3 pKd 18
pKd 9.3 (Kd 5x10-10 M) [18]
protriptyline Hs Inhibition 8.9 pKd 21
pKd 8.9 (Kd 1.41x10-9 M) [21]
atomoxetine Hs Inhibition 8.7 pKd 5
pKd 8.7 (Kd 2.03x10-9 M) [5]
[3H]nisoxetine Hs Inhibition 8.4 pKd
pKd 8.4 (Kd 4x10-9 M)
clomipramine Hs Inhibition 7.4 pKd 21
pKd 7.4 (Kd 3.8x10-8 M) [21]
nefazodone Hs Inhibition 6.4 pKd 5
pKd 6.4 (Kd 3.6x10-7 M) [5]
Description: Dissociation constant of [3H]- nisoxatine vs. nefazodone.
mazindol Hs Inhibition 8.9 pKi
pKi 8.9 (Ki 1.26x10-9 M)
desipramine Hs Inhibition 8.7 pKi 16
pKi 8.7 (Ki 2.1x10-9 M) [16]
nisoxetine Hs Inhibition 8.4 pKi
pKi 8.4 (Ki 3.98x10-9 M)
lofepramine Hs Inhibition 8.3 pKi 21
pKi 8.3 (Ki 5.4x10-9 M) [21]
duloxetine Hs Inhibition 8.2 pKi 17
pKi 8.2 (Ki 5.97x10-9 M) [17]
nortriptyline Hs Inhibition 8.2 pKi 7
pKi 8.2 (Ki 6.3x10-9 M) [7]
protriptyline Hs Inhibition 8.2 pKi 13
pKi 8.2 (Ki 6.8x10-9 M) [13]
H05 Rn Inhibition 8.2 pKi 27
pKi 8.2 (Ki 6.72x10-9 M) [27]
nomifensine Hs Inhibition 8.1 pKi
pKi 8.1 (Ki 7.94x10-9 M)
reboxetine Hs Inhibition 8.0 pKi 26
pKi 8.0 (Ki 1x10-8 M) [26]
maprotiline Hs Inhibition 7.9 pKi 9
pKi 7.9 (Ki 1.2x10-8 M) [9]
N-desalkylquetiapine Hs Inhibition 7.9 pKi 10
pKi 7.9 (Ki 1.2x10-8 M) [10]
amoxapine Hs Inhibition 7.9 pKi 3
pKi 7.9 (Ki 1.3x10-8 M) [3]
imipramine Hs Inhibition 7.8 pKi
pKi 7.8 (Ki 1.6x10-8 M)
mianserin Rn Inhibition 7.6 pKi 14
pKi 7.6 (Ki 2.6x10-8 M) [14]
Description: Inhibition of [3H]NE uptake into rat synaptosomes
doxepin Hs Inhibition 7.5 pKi 3
pKi 7.5 (Ki 2.9x10-8 M) [3]
dosulepin Hs Inhibition 7.3 pKi 21
pKi 7.3 (Ki 4.6x10-8 M) [21]
ziprasidone Rn Inhibition 7.3 pKi 1
pKi 7.3 (Ki 4.8x10-8 M) [1]
dexamfetamine Hs Inhibition 7.0 pKi 2
pKi 7.0 (Ki 1.01x10-7 M) [2]
dexmethylphenidate Rn Inhibition 6.6 pKi 11
pKi 6.6 (Ki 2.7x10-7 M) [11]
Description: Displacement of [3H]nisoxetine from NET in Sprague-Dawley rat cortical tissue.
amitriptyline Hs Inhibition 6.5 pKi 2
pKi 6.5 (Ki 3.33x10-7 M) [2]
bupropion Hs Inhibition 6.4 pKi 12
pKi 6.4 (Ki 4.41x10-7 M) [12]
desvenlafaxine Hs Inhibition <6.2 pKi 6
pKi <6.2 (Ki >6.5x10-7 M) [6]
quetiapine Hs Inhibition 6.0 pKi 10
pKi 6.0 (Ki 9.27x10-7 M) [10]
trimipramine Hs Inhibition 5.6 pKi 21
pKi 5.6 (Ki 2.45x10-6 M) [21]
solriamfetol Hs Inhibition 5.4 pKi 4
pKi 5.4 (Ki 3.7x10-6 M) [4]
Description: In a radioligand binding assay using HEK293 cells expressing hNET.
sibutramine Hs Inhibition 5.3 pKi 3
pKi 5.3 (Ki 5.619x10-6 M) [3]
tapentadol Hs Inhibition 5.1 pKi 23
pKi 5.1 (Ki 8.8x10-6 M) [23]
phenelzine Hs Inhibition <5.0 pKi 21
pKi <5.0 (Ki >1x10-5 M) [21]
citalopram Hs Inhibition <3.0 pKi 28
pKi <3.0 (Ki >1x10-3 M) [28]
Description: Inhibition of [3H]dopamine uptake at human NET expressed in COS7 cells.
milnacipran Hs Inhibition 9.1 pIC50 24
pIC50 9.1 (IC50 7.94x10-10 M) [24]
protriptyline Hs Inhibition 8.8 pIC50 15
pIC50 8.8 (IC50 1.7x10-9 M) [15]
Description: Inhibition of [3H]nisoxetine binding to CHO cells expressing hNET.
norzotepine Hs Inhibition 8.0 pIC50 20
pIC50 8.0 (IC50 1.1x10-8 M) [20]
levomilnacipran Hs Inhibition 7.4 pIC50 25
pIC50 7.4 (IC50 4x10-8 M) [25]
methylphenidate Hs Inhibition 7.2 pIC50
pIC50 7.2 (IC50 6.1x10-8 M)
zotepine Hs Inhibition 7.2 pIC50 20
pIC50 7.2 (IC50 7.1x10-8 M) [20]
venlafaxine Hs Inhibition 6.3 pIC50 19
pIC50 6.3 (IC50 5.35x10-7 M) [19]
solriamfetol Hs Inhibition 5.4 pIC50 4
pIC50 5.4 (IC50 4.4x10-6 M) [4]
Description: In a NE reuptake assay in HEK293 cells expressing hNET.
View species-specific inhibitor tables
Inhibitor Comments
Protriptyline has also been shown to inhibit uptake of 5-HT in platelet rich human plasma [22].
Venlafaxine has a lower IC50 for SERT than for NET, therefore SERT has been tagged as the drug's primary target.
Clinically-Relevant Mutations and Pathophysiology
Disease:  Orthostatic intolerance
OMIM: 604715


Show »

1. Ablordeppey SY, Altundas R, Bricker B, Zhu XY, Kumar EV, Jackson T, Khan A, Roth BL. (2008) Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg. Med. Chem., 16 (15): 7291-301. [PMID:18595716]

2. Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S. (2013) An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg. Med. Chem. Lett., 23 (11): 3411-5. [PMID:23602445]

3. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix,

4. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A. (2018) Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J. Pharmacol. Exp. Ther., 366 (2): 367-376. [PMID:29891587]

5. Carlier PR, Lo MM, Lo PC, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA. (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg. Med. Chem. Lett., 8 (5): 487-92. [PMID:9871604]

6. Dreyfus N, Myers JK, Badescu VO, de Frutos O, de la Puente ML, Ding C, Filla SA, Fynboe K, Gernert DL, Heinz BA et al.. (2013) Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett, 4 (6): 560-4. [PMID:24900709]

7. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK. (2000) 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J. Med. Chem., 43 (5): 1011-8. [PMID:10715164]

8. Gu HH, Wall S, Rudnick G. (1996) Ion coupling stoichiometry for the norepinephrine transporter in membrane vesicles from stably transfected cells. J. Biol. Chem., 271 (12): 6911-6. [PMID:8636118]

9. Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA et al.. (2009) Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles. Bioorg. Med. Chem., 17 (22): 7802-15. [PMID:19836247]

10. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology, 33 (10): 2303-12. [PMID:18059438]

11. Kim DI, Deutsch HM, Ye X, Schweri MM. (2007) Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J. Med. Chem., 50 (11): 2718-31. [PMID:17489581]

12. Lapinsky DJ, Aggarwal S, Huang Y, Surratt CK, Lever JR, Foster JD, Vaughan RA. (2009) A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg. Med. Chem., 17 (11): 3770-4. [PMID:19442525]

13. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J. Med. Chem., 51 (22): 7094-8. [PMID:18983139]

14. Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR. (1984) Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J. Med. Chem., 27 (8): 943-6. [PMID:6747993]

15. Mladenova G, Annedi SC, Ramnauth J, Maddaford SP, Rakhit S, Andrews JS, Zhang D, Porreca F. (2012) First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain. J. Med. Chem., 55 (7): 3488-501. [PMID:22420844]

16. O'Neill DJ, Adedoyin A, Alfinito PD, Bray JA, Cosmi S, Deecher DC, Fensome A, Harrison J, Leventhal L, Mann C et al.. (2010) Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J. Med. Chem., 53 (11): 4511-21. [PMID:20462211]

17. Pechulis AD, Beck JP, Curry MA, Wolf MA, Harms AE, Xi N, Opalka C, Sweet MP, Yang Z, Vellekoop AS et al.. (2012) 4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors. Bioorg. Med. Chem. Lett., 22 (23): 7219-22. [PMID:23084899]

18. Raffel DM, Chen W. (2004) Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch. Pharmacol., 370 (1): 9-16. [PMID:15300361]

19. Sabatucci JP, Mahaney PE, Leiter J, Johnston G, Burroughs K, Cosmi S, Zhang Y, Ho D, Deecher DC, Trybulski E. (2010) Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett., 20 (9): 2809-12. [PMID:20378347]

20. Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, Harada K, Ni K, Matsuoka N. (2010) Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J. Pharmacol. Exp. Ther., 333 (3): 772-81. [PMID:20223878]

21. Tatsumi M, Groshan K, Blakely RD, Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol., 340 (2-3): 249-58. [PMID:9537821]

22. Trenchard A, Turner P, Pare CM, Hills M. (1975) The effects of protriptyline and clomipramine in vitro on the uptake of 5-hydroxytryptamine and dopamine in human platelet-rich plasma. Psychopharmacologia, 43 (1): 89-93. [PMID:1161997]

23. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E et al.. (2007) (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther., 323 (1): 265-76. [PMID:17656655]

24. Van Orden LJ, Van Dyke PM, Saito DR, Church TJ, Chang R, Smith JA, Martin WJ, Jaw-Tsai S, Stangeland EL. (2013) A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships. Bioorg. Med. Chem. Lett., 23 (5): 1456-61. [PMID:23347683]

25. Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L et al.. (2008) Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett., 18 (11): 3230-5. [PMID:18468895]

26. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A et al.. (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry, 47 (9): 818-29. [PMID:10812041]

27. Xu X, Wei Y, Guo Q, Zhao S, Liu Z, Xiao T, Liu Y, Qiu Y, Hou Y, Zhang G et al.. (2018) Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. J. Pharmacol. Exp. Ther., 365 (3): 624-635. [PMID:29615471]

28. Zhang P, Jørgensen TN, Loland CJ, Newman AH. (2013) A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg. Med. Chem. Lett., 23 (1): 323-6. [PMID:23168018]


Show »

How to cite this page

Select citation format: